Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease
Reeve, Janice L. V.
Duffy, Angela M.
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 88 times in Scopus (view citations)
Reeve, Janice L. V. Duffy, Angela M.; O'Brien, Timothy; Samali, Afshin (2005). Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. Journal of Cellular and Molecular Medicine 9 (3), 609-622
Cardiovascular disease is a leading cause of death worldwide. Loss of function or death of cardiomyocytes is a major contributing factor to these diseases. Cell death in conditions such as heart failure and myocardial infarction is associated with apoptosis. Apoptotic pathways have been well studied in non-myocytes and it is thought that similar pathways exist in cardiomyocytes. These pathways include death initiated by ligation of membrane-bound death receptors, release of pro-apoptotic factors from mitochondria or stress at the endoplasmic reticulum. The key regulators of apoptosis include inhibitors of caspases (IAPs), the Bcl-2 family of proteins, growth factors, stress proteins, calcium and oxidants. The highly organized and predictive nature of apoptotic signaling means it is amenable to manipulation. A thorough understanding of the apoptotic process would facilitate intervention at the most suitable points, alleviating myocardium decline and dysfunction. This review summarizes the mechanisms underlying apoptosis and the mediators/regulators involved in these signaling pathways. We also discuss how the potential therapeutic value of these molecules could be harnessed.
Showing items related by title, author, creator and subject.
The trail-receptor-1: trail-receptor-3 and -4 ratio is a predictor for trail sensitivity of cancer cells Zwacka, (Spandidos Publications, 2009-04-06)The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a ...
O’ Reilly, Eimear; Tirincsi, Andrea; Logue, Susan E.; Szegezdi, Eva (Frontiers Media SA, 2016-10-31)Cancer immune surveillance is essential for the inhibition of carcinogenesis. Malignantly transformed cells can be recognized by both the innate and adaptive immune systems through different mechanisms. Immune effector ...
Szegezdi, Eva; Reis, Carlos R.; Sloot, Almer M. van der; Natoni, Alessandro; O’Reilly, Aoife; Reeve, Janice; Cool, Robbert H.; O’Dwyer, Michael; Knapper, Steven; Serrano, Luis; Quax, Wim J.; Samali, Afshin (Wiley-Blackwell, 2011-09-26)Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different ...